Free Trial

Novavax (NVAX) 10K Form and Latest SEC Filings 2026

Novavax logo
$9.26 -0.10 (-1.09%)
As of 01:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Novavax SEC Filings & Recent Activity

Novavax (NASDAQ:NVAX) has submitted 496+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Novavax's financial statements. The most recent filing was a Form 8-K submitted on May 6, 2026.

Form 4
NOVAVAX INC Reports Ownership Change on Apr. 28, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Novavax Files Current Report on May. 6, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Novavax Files Quarterly Report on May. 6, 2026

The 10-Q contains Novavax's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Novavax SEC Filing History

Browse Novavax's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/06/2026 7:00 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2026 6:50 AM
Novavax (1000694) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/30/2026 11:07 AM
Novavax (1000694) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/28/2026 4:00 PM
Newton Charles W. (1866219) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/27/2026 12:02 PM
BANK OF AMERICA CORP /DE/ (70858) Filed by
Novavax (1000694) Subject
Form SCHEDULE 13G/A
04/27/2026 9:09 AM
Novavax (1000694) Filer
Form ARS
04/27/2026 7:00 AM
Novavax (1000694) Filer
Form DEF 14A
04/27/2026 7:00 AM
Novavax (1000694) Filer
Form DEFA14A
04/16/2026 5:13 PM
Novavax (1000694) Issuer
Walker Robert Edward (2127840) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2026 4:40 PM
Novavax (1000694) Issuer
Walker Robert Edward (2127840) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/08/2026 5:00 AM
Novavax (1000694) Subject
SHAH CAPITAL MANAGEMENT (1383838) Filed by
Form SCHEDULE 13D/A
03/09/2026 5:06 PM
Novavax (1000694) Issuer
O'Hara Elaine (1968045) Reporting
Form 4/A
03/09/2026 5:08 PM
Jacobs John C (1820836) Reporting
Novavax (1000694) Issuer
Form 4/A
03/09/2026 5:09 PM
Casey Mark J (1415297) Reporting
Novavax (1000694) Issuer
Form 4/A
03/09/2026 5:11 PM
Draghia-Akli Ruxandra (2041719) Reporting
Novavax (1000694) Issuer
Form 4/A
03/09/2026 5:12 PM
Kelly James Patrick (1506314) Reporting
Novavax (1000694) Issuer
Form 4/A
03/09/2026 5:13 PM
Kelly James Patrick (1506314) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:00 AM
Draghia-Akli Ruxandra (2041719) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:01 AM
Casey Mark J (1415297) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:02 AM
Novavax (1000694) Issuer
O'Hara Elaine (1968045) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:03 AM
Jacobs John C (1820836) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:04 AM
Kelly James Patrick (1506314) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 8:33 PM
Casey Mark J (1415297) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 8:34 PM
Novavax (1000694) Issuer
O'Hara Elaine (1968045) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 8:35 PM
Kelly James Patrick (1506314) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 8:37 PM
Jacobs John C (1820836) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 7:02 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2026 6:33 AM
Novavax (1000694) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/11/2026 1:11 PM
BANK OF AMERICA CORP /DE/ (70858) Filed by
Novavax (1000694) Subject
Form SCHEDULE 13G
02/09/2026 6:56 AM
Novavax (1000694) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
01/26/2026 6:57 PM
Jacobs John C (1820836) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 5:59 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/12/2026 7:01 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 4:23 PM
Draghia-Akli Ruxandra (2041719) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2025 6:47 AM
Novavax (1000694) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 7:00 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2025 5:02 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/30/2025 3:30 PM
Novavax (1000694) Issuer
Rodgers Richard J (1313397) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2025 6:00 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/14/2025 6:45 AM
Novavax (1000694) Subject
SHAH CAPITAL MANAGEMENT (1383838) Filed by
Form SCHEDULE 13D/A
10/07/2025 6:00 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/27/2025 3:38 PM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/27/2025 3:40 PM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2025 6:48 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2025 7:04 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2025 6:47 AM
Novavax (1000694) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/24/2025 5:37 PM
DOUGLAS RICHARD (1021015) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:39 PM
King Rachel K. (1589712) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:40 PM
MOTT DAVID M (1219871) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:40 PM
Novavax (1000694) Issuer
Rodgers Richard J (1313397) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:35 PM
MCGLYNN MARGARET G (1215126) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:36 PM
Alton Gregg H (1334682) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:03 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2025 8:39 PM
MOTT DAVID M (1219871) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 8:40 PM
Novavax (1000694) Issuer
Rodgers Richard J (1313397) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 8:41 PM
King Rachel K. (1589712) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 8:36 PM
DOUGLAS RICHARD (1021015) Reporting
Novavax (1000694) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2025 6:01 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2025 6:34 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2025 7:26 AM
Novavax (1000694) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2025 6:59 AM
Novavax (1000694) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Novavax SEC Filings - Frequently Asked Questions

Novavax (NVAX) has submitted 496+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Novavax's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Novavax's financial statements page.

The most recent filing was a Form 8-K submitted on May 6, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:NVAX) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners